NL
VRTX icon

NWAM LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

NWAM LLC’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.03M Buy
10,129
+3,797
+60% +$1.68M 0.25% 93
2026
Q1 		$2.83M Buy
6,332
+1,294
+26% +$603K 0.16% 133
2025
Q4 		$2.4M Sell
5,038
-39
-0.8% -$16.8K 0.13% 155
2025
Q3 		$2.12M Sell
5,077
-10
-0.2% -$4.18K 0.12% 177
2025
Q2 		$2.32M Buy
5,087
+345
+7% +$159K 0.13% 158
2025
Q1 		$2.3M Sell
4,742
-1,436
-23% -$669K 0.2% 114
2024
Q4 		$2.49M Buy
6,178
+1,178
+24% +$546K 0.15% 144
2024
Q3 		$2.33M Buy
5,000
+8
+0.2% +$3.84K 0.14% 151
2024
Q2 		$2.34M Buy
4,992
+132
+3% +$57.3K 0.69% 29
2024
Q1 		$1.99M Sell
4,860
-2
-0% -$845 0.16% 127
2023
Q4 		$1.98M Buy
4,862
+11
+0.2% +$4.06K 0.16% 130
2023
Q3 		$1.69M Sell
4,851
-10
-0.2% -$3.5K 0.17% 121
2023
Q2 		$1.71M Sell
4,861
-12
-0.2% -$4.04K 0.14% 144
2023
Q1 		$1.54M Sell
4,873
-75
-2% -$22.5K 0.16% 137
2022
Q4 		$1.43M Buy
4,948
+30
+0.6% +$9.14K 0.13% 170
2022
Q3 		$1.42M Buy
4,918
+106
+2% +$30.5K 0.14% 154
2022
Q2 		$1.39M Sell
4,812
-961
-17% -$257K 0.13% 160
2022
Q1 		$1.51M Sell
5,773
-1
-0% -$237 0.12% 178
2021
Q4 		$1.27M Buy
5,774
+3,339
+137% +$649K 0.1% 204
2021
Q3 		$442K Buy
+2,435
New +$475K 0.04% 346
2020
Q3 		– Sell
-1,169
Closed -$339K – 427
2020
Q2 		$339K Buy
+1,169
New +$317K 0.05% 307
2019
Q4 		$277K Buy
+1,263
New +$256K 0.05% 313

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

NWAM LLC's VRTX Position: Q2 2026 in Review

NWAM LLC increased its Vertex Pharmaceuticals (VRTX) stake by 60% in Q2 2026, buying an estimated $1.68M and bringing the position to 10,129 shares worth $5.03M. The position accounts for 0.25% of the portfolio, ranked #93.

NWAM LLC first reported a position in VRTX in Q4 2019 and has held it in 22 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • NWAM LLC held 10,129 shares of Vertex Pharmaceuticals worth $5.03M as of Q2 2026.
  • NWAM LLC bought 3,797 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.68M.
  • Vertex Pharmaceuticals made up 0.25% of NWAM LLC's portfolio in Q2 2026, its #93 holding.
  • NWAM LLC first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on NWAM LLC's 13F filing for Q2 2026, filed 23 Jul 2026.